Anne Wojcicki

Imagine this: you spit in a tube, mail it off, and weeks later, you're holding the secrets to your DNA.

Your health risks, ancestry, and even traits like whether cilantro tastes like soap.

Crazy, right? Anne Wojcicki made it a reality.

In 2006, while healthcare profited from treating illness, Anne had a wild idea: What if we empowered people to prevent it?

She co-founded 23andMe to give everyone access to their genetic data, flipping the script on a system designed to keep patients in the dark.

But the journey was anything but smooth.

When the FDA shut down 23andMe’s health reports in 2013, critics predicted it was game over.

But Anne refused to quit.

She battled regulators, redesigned the product, and became the only company allowed to deliver health insights directly to consumers.

And she didn’t stop there.

Anne saw potential in 23andMe’s massive database… millions of people sharing genetic data and health surveys.

She turned it into a crowdsourced research engine, fueling drug discoveries faster than Big Pharma.

Her boldness landed a $300M deal with GlaxoSmithKline to develop treatments for diseases like cancer.

But not everyone loved her approach.

Anne’s determination to control the company led to clashes with her board and a high-stakes drama that rocked Silicon Valley.

Critics called her leadership too centralized.

Anne called it focus.

“This isn’t just a company,” she said. “It’s a mission to revolutionize healthcare.”